gamma‐secretase modulation: from bench to clinic

作者
Kevin D. Rynearson
出处
期刊:Alzheimers & Dementia [Wiley]
卷期号:20 (S6)
标识
DOI:10.1002/alz.090509
摘要

Abstract Cerebral beta‐amyloid accumulation is the key initiator of Alzheimer’s disease (AD) pathology. Most familial early‐onset AD mutations in the APP, PSEN1/2 genes increase the ratio of Abeta42:Abeta40, which drives beta‐amyloid accumulation in the brain. In 2001, the late Steve Wagner, Maria Kounnas, and I directed an agnostic high‐throughput screen for compounds that would reverse the Abeta42:Abeta40, ratio, and discovered the first non‐NSAID (second generation) gamma secretase modulators (GSM) at TorreyPines Therapeutics. Since then, in academia, we designed several novel structures similar to, but distinct from our original GSMs with predicted higher aqueous solubility. These compounds were then developed in the Wagner and Tanzi labs at UCSD and MGH, respectively with funding from the NIH and Cure Alzheimer’s Fund. Importantly, unlike gamma secretase inhibitors, our GSMs do not inhibit γ‐secretase activity, i.e. do not significantly inhibit NOTCH cleavage (up to 25 uM), but, instead, allosterically modulate gamma secretase activity, reducing generation of Aβ42 and to a lesser extent Aβ40, while enhancing production of Aβ37 and Aβ38, with IC50’s in the low nanomolar range. The preclinical development of our GSM’s evolved into four distinct chemical classes and involved testing over 1000 analogs, leading to our main clinical candidate, GSM776890, for which an IND has been submitted to the FDA (sponsored by Acta Pharmaceuticals, Boston). GSM776890 exhibits robust time‐ and dose‐dependent efficacy in both acute and chronic studies across various species, including a transgenic AD mouse model. GSM776890 displayed a >40‐fold safety margin in rats, with no observed adverse effects to the 50% effective AUC or AUC effective, which is needed to reduce Aβ42 levels by 50% in rat brain (Rynearson et al. JEM, 2021). Given the recent success of Abeta immunotherapy in clinical trials, GSM776890 represents an oral molecule alternate to managing beta‐amyloid levels as means for preventing and treating AD.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cc完成签到,获得积分10
刚刚
JWD完成签到 ,获得积分10
刚刚
2秒前
2秒前
水水的完成签到 ,获得积分10
2秒前
爱吃香菜发布了新的文献求助10
2秒前
甜甜的流沙完成签到,获得积分10
2秒前
yu完成签到 ,获得积分10
2秒前
黄日华不分先后热大完成签到,获得积分10
3秒前
蜡笔是土豆韦德完成签到,获得积分10
3秒前
星遨完成签到,获得积分10
4秒前
勤恳藏花完成签到,获得积分10
4秒前
李爱国的应助被蓝天采纳,获得10
4秒前
乐空思的应助被康乐采纳,获得50
4秒前
5秒前
南海子完成签到,获得积分10
5秒前
TT完成签到,获得积分10
5秒前
黑色幽默完成签到,获得积分10
5秒前
巫惜海完成签到,获得积分20
5秒前
6秒前
菁菁完成签到,获得积分20
6秒前
夏日气泡水完成签到 ,获得积分10
6秒前
灵运完成签到,获得积分10
7秒前
虚幻缘郡完成签到,获得积分10
7秒前
8秒前
巫惜海发布了新的文献求助10
8秒前
8秒前
开心枣枣完成签到 ,获得积分10
8秒前
8秒前
9秒前
菁菁发布了新的文献求助10
9秒前
xigua123完成签到,获得积分10
9秒前
10秒前
cdercder的应助被楠楠采纳,获得10
10秒前
文静冰露发布了新的文献求助10
11秒前
李密发布了新的文献求助10
11秒前
12秒前
暴躁月亮发布了新的文献求助20
13秒前
fnana发布了新的文献求助10
13秒前
微风无起发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177849
求助须知:如何正确求助?哪些是违规求助? 9568641
关于积分的说明 21800145
捐赠科研通 7772473
什么是DOI,文献DOI怎么找? 3432537
关于科研通互助平台的介绍 2556720
邀请新用户注册赠送积分活动 2478067